LYS006 + Tropifexor
Phase 2Terminated 0 views this week 0 watching💤 Quiet
Interest: 27/100
27
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Non-alcoholic Fatty Liver Disease
Conditions
Non-alcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis
Trial Timeline
Jun 4, 2020 → Jan 6, 2022
NCT ID
NCT04147195About LYS006 + Tropifexor
LYS006 + Tropifexor is a phase 2 stage product being developed by Novartis for Non-alcoholic Fatty Liver Disease. The current trial status is terminated. This product is registered under clinical trial identifier NCT04147195. Target conditions include Non-alcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis.
What happened to similar drugs?
0 of 4 similar drugs in Non-alcoholic Fatty Liver Disease were approved
Approved (0) Terminated (0) Active (4)
Hype Score Breakdown
Clinical
12
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04147195 | Phase 2 | Terminated |
Competing Products
20 competing products in Non-alcoholic Fatty Liver Disease